Generics Bulletin editor Dave Wallace looks at everything that's important to the generics, biosimilars and value-added medicines industries. All views my own.
Joined March 2019
- Tweets129
- Following114
- Followers129
- Likes11
Dave Wallace, Generics Bulletin executive editor retweeted
Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount
bit.ly/3DusTxT
Dave Wallace, Generics Bulletin executive editor retweeted
Shortlist Unveiled For GGB Awards
bit.ly/3BQWMXF
Dave Wallace, Generics Bulletin executive editor retweeted
In this @Pharma_Intell interview, #AAMBoard Vice Chair Christine Baeder (Senior Vice President, Chief Operating Officer for US Generics @TevaUSA) explores the challenges and opportunities of #ComplexGenerics.
Read: generics.pharmaintelligence.…
Dave Wallace, Generics Bulletin executive editor retweeted
Biosimilars Forum executive director Juliana Reed discusses the Forum's priorities and leadership in the #biosimilars industry in an interview with @DaveGenerics @Genericbulletin Read more here: generics.pharmaintelligence.…
Dave Wallace, Generics Bulletin executive editor retweeted
This is the first part of an exclusive two-part interview with David Wallace at @Genericbulletin, where I talk about Alvotech’s plans to move forward following the SPAC merger, partnerships, and strategy on our biosimilars journey. bit.ly/3rhti0V
Dave Wallace, Generics Bulletin executive editor retweeted
Thanks for a great night at the #GGBAwards. A big shout out to all the entries for this year’s #CSR Initiative of the Year award. It’s so encouraging to see all the great work the Generics sector is doing to support people in need. @Genericbulletin @DaveGenerics
Dave Wallace, Generics Bulletin executive editor retweeted
Finally, our last award of the night, sponsored by IQVIA, goes to Celltrion Healthcare (taking home the hat-trick!) for Company of the Year! Well done and congratulations to all of tonight’s winners! #GGBAwards
Dave Wallace, Generics Bulletin executive editor retweeted
We are attending the @GGB_Awards in Milan next week, where we will be presenting the '#CSR Initiative of the Year' award to the company that’s been setting the pace in corporate social responsibility in 2021. We’re looking forward to meeting some of you there!
Dave Wallace, Generics Bulletin executive editor retweeted
Shortlist Revealed For GGB Awards
bit.ly/3Ej6EKa
Dave Wallace, Generics Bulletin executive editor retweeted
Biosimilars Players Climb Global Rankings
bit.ly/3sbXeKH
Dave Wallace, Generics Bulletin executive editor retweeted
Ups And Downs See Mid-Table Players Shift Position
bit.ly/3CDjHW6
Dave Wallace, Generics Bulletin executive editor retweeted
Pfizer Takes ‘Opportunistic’ Approach To Future Biosimilars
bit.ly/2TIT14z
Dave Wallace, Generics Bulletin executive editor retweeted
Watch the launch video of the #IGBA whitepaper 'A Vision for the Global Generic and Biosimilar Medicines Industry' which covers the strong contribution of the #pharmaceutical sector to global health outcomes and economies, Vision 2030, etc.
Watch here: bit.ly/3hPTx8D
Dave Wallace, Generics Bulletin executive editor retweeted
Philip Morris Bid For Vectura Trumps Carlyle Takeover
bit.ly/3i81vuj
Dave Wallace, Generics Bulletin executive editor retweeted
Who’s Hired? Accord’s Burt Moves On
bit.ly/3dWIwl8
Dave Wallace, Generics Bulletin executive editor retweeted
Lupin Responds To FDA Warning Letter
bit.ly/368pGD8
Dave Wallace, Generics Bulletin executive editor retweeted
What’s Next? Five Things To Look Out For In July
bit.ly/2UWyh9I
Dave Wallace, Generics Bulletin executive editor retweeted
Indian Leaders Begin Unique Collaboration On Molnupiravir
bit.ly/3Am6wrs
Dave Wallace, Generics Bulletin executive editor retweeted
Read an interview with #AAMboard member Keren Haruvi, President of Sandoz US and Head of North America, @Sandoz_Global. generics.pharmaintelligence.…
Dave Wallace, Generics Bulletin executive editor retweeted
Sandoz Aims To Be ‘First In And Last Out’ In North America
bit.ly/30JRfQy